SCHEMBL3518924

SCHEMBL3518924

COC(=O)c1c(OC)c(-c2cccc(F)c2)cc2ncc(Cl)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 1/20 0.41
CSNK1D P48730 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
DYRK1A Q13627 1/20 0.41
NTRK2 Q16620 1/20 0.41
AURKB Q96GD4 1/20 0.41
PDGFRB P09619 1/20 0.41
PDGFRA P16234 1/20 0.41
DHODH Q02127 2/20 0.38
TACR3 P29371 2/20 0.38
CTSA P10619 1/20 0.38
FYN P06241 2/20 0.38
GRIN2B Q13224 2/20 0.37
POLQ O75417 1/20 0.37
PLA2G2A P14555 1/20 0.37
MAPK14 Q16539 1/20 0.36
TOP2A P11388 1/20 0.35
TUBB4A P04350 2/20 0.35
TUBB P07437 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3521378 0.78 PDGFRB (0.37) PDGFRBPDGFRAGRIN2BPOLQPLA2G2A
SCHEMBL3518053 0.78 RPS6KB1 (0.39) RPS6KB1CSNK1DGSK3AGSK3BDYRK1A
SCHEMBL3517844 0.78 RPS6KB1 (0.41) RPS6KB1CSNK1DGSK3AGSK3BDYRK1A
SCHEMBL3522414 0.77 RPS6KB1 (0.40) RPS6KB1CSNK1DGSK3AGSK3BDYRK1A
SCHEMBL3520739 0.76 SMN1; SMN2 (0.46) PDGFRBPLA2G2AGABRA5
SCHEMBL3525976 0.76 CTSA (0.39) RPS6KB1CSNK1DGSK3AGSK3BDYRK1A
SCHEMBL3521115 0.76 CSNK1D (0.39) RPS6KB1CSNK1DGSK3AGSK3BDYRK1A
SCHEMBL3520504 0.76 RPS6KB1 (0.41) RPS6KB1CSNK1DGSK3AGSK3BDYRK1A
SCHEMBL3521833 0.71 PTK2 (0.39) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3523225 0.71 MAPT (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 RPS6KB1 1405/4885CSNK1D 2540/4885GSK3A 2970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.